The chemical class of IL-3Rβ inhibitors encompasses a diverse group of compounds characterized by their ability to modulate the activity of the Interleukin-3 receptor beta subunit (IL-3Rβ). This protein is a critical component of the cell signaling mechanism, primarily involved in the hematopoietic system where it plays a pivotal role in the growth and differentiation of various blood cells. The inhibitors in this class are designed to target and bind to IL-3Rβ, thus impeding its interaction with its natural ligand, Interleukin-3 (IL-3). This inhibition can lead to a downstream effect on the signaling pathways that are normally activated by the IL-3/IL-3Rβ interaction, ultimately influencing cell proliferation and survival processes. The compounds classified as IL-3Rβ inhibitors are diverse in their structure and mode of action. Some of these inhibitors are small molecules that bind directly to the receptor's active site, blocking IL-3 binding and subsequent receptor activation. Others may function allosterically, modifying the receptor's conformation to reduce its affinity for IL-3. Moreover, certain inhibitors might interfere with the receptor's expression or its post-translational modifications, such as glycosylation, which are crucial for its proper functioning. The specificity and efficacy of these inhibitors are contingent upon their ability to selectively target IL-3Rβ without affecting other closely related receptors in the body, which is a significant consideration in their development.
The impact of these inhibitors spans various aspects of cellular function, primarily in the hematopoietic system where IL-3Rβ has a significant role. By modulating the activity of IL-3Rβ, these inhibitors can influence the survival, proliferation, and differentiation of blood cells, which has implications in understanding cellular processes under normal and abnormal physiological conditions. The development and study of IL-3Rβ inhibitors are driven by the need to understand the intricate mechanisms of cell signaling pathways and their roles in various biological processes. These compounds offer valuable tools for research in cellular biology, providing insights into the complex network of interactions that govern cell behavior and function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
A selective inhibitor of BMP signaling. It inhibits ACVR1B by preventing phosphorylation of SMAD1/5/8. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $209.00 $312.00 $620.00 $1026.00 | 2 | |
Selectively inhibits BMP signaling; blocks ACVR1B kinase activity. | ||||||
K02288 | 1431985-92-0 | sc-488981 | 5 mg | $330.00 | ||
Potent and selective ALK2 inhibitor, affecting ACVR1B-related pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
Selective inhibitor of ALK4, ALK5, and ALK7, impacting TGF-β/Activin/Nodal signaling. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
Selects against VEGFR2 and other kinases, specifically inhibiting BMP type I receptors including ACVR1B. | ||||||
SAG | 912545-86-9 | sc-212905 sc-212905A | 1 mg 5 mg | $163.00 $413.00 | 27 | |
Inhibits ALK4, ALK5, ALK7, and ACVR1B, modulating TGF-β signaling. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Inhibits BMP signaling and is a potent inhibitor of AMPK, affecting ACVR1B activity. | ||||||
LDN 193719 | 1062368-49-3 | sc-489383 | 10 mg | $189.00 | ||
Dual inhibitor of BMP receptor and ALK2/3, affecting ACVR1B. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
Inhibits TGF-β signaling; suppresses phosphorylation of SMAD2/3, impacting ACVR1B indirectly. | ||||||
IN-1130 | 868612-83-3 | sc-507462 | 25 mg | $435.00 | ||
TGF-β receptor inhibitor, can indirectly affect ACVR1B signaling. |